drugset
drugset / Trial / NCT00104429

GW873140 In Combination With Combivir In HIV Infected Subjects

NCT00104429 ↗

Phase 2 Terminated 125 enrolled ViiV Healthcare
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a 96-week study designed to evaluate the safety and efficacy of GW873140 in combination with Combivir in HIV infected, untreated subjects.

Timeline

Start
2005-01
Primary completion
2006-01
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Subject APLAVIROC Small molecule — —
Background Lamivudine Other / unclassified — —

Indications

HIV infectious disease